746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors.

MLA

O’Donnell, P., et al. “746P EV-201: Long-Term Results of Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Platinum and PD-1/PD-L1 Inhibitors.” Annals of Oncology, vol. 31, Sept. 2020, pp. S579–80. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.818.

APA

O’Donnell, P., Galsky, M. D., Rosenberg, J. E., Petrylak, D. P., Balar, A. V., McGregor, B. A., Heath, E., Yu, E. Y., Quinn, D. I., Hahn, N. M., Campbell, M., Liang, S.-Y., Steinberg, J., & Loriot, Y. (2020). 746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors. Annals of Oncology, 31, S579–S580. https://doi.org/10.1016/j.annonc.2020.08.818

Chicago

O’Donnell, P., M.D. Galsky, J.E. Rosenberg, D.P. Petrylak, A.V. Balar, B.A. McGregor, E. Heath, et al. 2020. “746P EV-201: Long-Term Results of Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Platinum and PD-1/PD-L1 Inhibitors.” Annals of Oncology 31 (September): S579–80. doi:10.1016/j.annonc.2020.08.818.